Skip to main content
OPRX
NASDAQ Trade & Services

OptimizeRx 10-Q: Q3 Revenue Down 17%, Net Income $1.2M, Material Weakness Persists

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$7.34
Mkt Cap
$138.256M
52W Low
$4.54
52W High
$16.37
52W Position info
62% above low
Off High info
55% below high
Rel. Volume info
3.3× avg
Market data snapshot near publication time

OPRX sits 62% above its 52-week low of $4.54 on elevated volume (3.3× avg).

Summary

OptimizeRx's Q3 10-Q shows revenue down 17% to $21.6M but net income of $1.2M ($0.06/share) on cost cuts, retention sliding to 83%, and a previously identified material weakness in disclosure controls still not fully remediated.


Key Events · Earnings and Guidance · OPRX

  • Q3 Revenue Falls 17%

    Net revenue was $21,615K versus $26,067K a year ago, and nine-month revenue fell 20% to $61,963K from $77,190K.

  • Cost Cuts Lift Profitability

    Total expenses dropped 21% to $18,945K, producing operating income of $2,670K and net income of $1,195K, or $0.06 per diluted share.

  • Retention Slides to 83%

    Net revenue retention fell to 83% from 121%, and a customer that was about 10% of fiscal 2025 revenue generated no revenue this period.

  • Material Weakness Still Open

    Disclosure controls were not effective due to a previously identified material weakness over third-party service organization data; three of four providers are remediated and one remains in process.


Analysis · OPRX · Trade & Services

The 10-Q confirms the quarter the 8-K flagged: revenue fell 17% to $21.6M while cost cuts lifted operating income to $2.7M and net income to $1.2M, or $0.06 a share. Demand is the bigger issue — net revenue retention dropped to 83% from 121% as large accounts cut spend, and one customer that was ~10% of 2025 revenue generated nothing this period. The filing also restates that disclosure controls were not effective because of a previously identified material weakness tied to third-party service organization data, with one of four providers still being remediated. The balance sheet is the offset: $22.3M cash, $42.5M working capital, debt paid down to $13.4M and a further $3.0M repaid on October 19, 2026.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OPRX was trading at $7.34 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $138.3M. The 52-week trading range was $4.54 to $16.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OPRX - Latest Insights

OPRX
Nov 13, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.34
Real-time Price: $7.34 info
Change: $0 (0%) info
Market Cap: $138.256M info
OPRX
Nov 11, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $8.91
Real-time Price: $7.34 info
Change: -$1.57 (-18%) info
Market Cap: $138.256M info
OPRX
Aug 12, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.04
Real-time Price: $7.34 info
Change: +$0.300 (+4%) info
Market Cap: $138.256M info
OPRX
Aug 12, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.04
Real-time Price: $7.34 info
Change: +$0.300 (+4%) info
Market Cap: $138.256M info
OPRX
Jun 12, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.23
Real-time Price: $7.34 info
Change: +$2.11 (+40%) info
Market Cap: $138.256M info